Biomarkers and classical Hodgkin lymphoma v1 (BACH)
Research type
Research Study
Full title
Evaluation of biomarkers in the management of classical Hodgkin lymphoma, with a focus on CCL17
IRAS ID
188181
Contact name
Ruth F Jarrett
Contact email
Sponsor organisation
NHS GG&C R&D
Clinicaltrials.gov Identifier
South East Coast - Surrey REC, 16/LO/0451
Duration of Study in the UK
1 years, 2 months, 31 days
Research summary
Classical Hodgkin lymphoma is a curable disease; however, many patients experience late side-effects of treatment and these cause significant morbidity and mortality. In addition, 10-20% of patients die of their disease. There is therefore a well-recognized need to develop biomarkers to guide treatment decisions in order to reduce side-effects in low risk patients and reduce treatment failure in high risk patients. The chemokine CCL17 shows promise as a biomarker of disease activity and treatment response. Serum and plasma CCL17 levels are very high in pre-treatment samples from most patients and fall rapidly following treatment. After two cycles of chemotherapy, CCL17 levels are usually within the normal range and raised levels at this, or later, time points suggest a poor response to treatment. At present interim PET-CT scans are used to assess treatment response but it is possible that CCL17 level could provide additional information, or be an alternative in some cases.
The main aim of the present study is to develop a point-of-care test for CCL17 in order to provide test results in a timescale that would be clinically useful in the clinical management of classical Hodgkin lymphoma. Serum samples collected as part of this study will be used in the development and validation of this test. Sequential serum samples and clinical data will be collected to inform the design of a larger study validating and refining the use of CCL17 in Hodgkin lymphoma. Samples will also be stored for use in future studies of biomarkers and classical Hodgkin lymphoma.
REC name
London - Surrey Research Ethics Committee
REC reference
16/LO/0451
Date of REC Opinion
16 Mar 2016
REC opinion
Further Information Favourable Opinion